DGIdb - TIVOZANIB Drug Record

TIVOZANIB chembl:CHEMBL1289494 ApprovedAntineoplastic

Alternate Names:

KRN-951
TIVOZANIB
KIL-8951
KIL8951
ASP-4130
AV-951
FOTIVDA
VEGFR TYROSINE KINASE INHIBITOR IV
drugbank:11800
chembl:CHEMBL1289494
pubchem.compound:9911830
chemidplus:475108-18-0

Drug Info:

FDA Approval	not approved
Drug Class	Small molecule
Drug Indications	antineoplastic agent
Drug Class	Kinase Inhibitors

(5 More Sources)

Publications:

Proia et al., 2015, 23814, an Inhibitory Antibody of Ligand-Mediated Notch1 Activation, Modulates Angiogenesis and Inhibits Tumor Growth without Gastrointestinal Toxicity., Mol. Cancer Ther.
Friedman et al., 2015, Landscape of Targeted Anti-Cancer Drug Synergies in Melanoma Identifies a Novel BRAF-VEGFR/PDGFR Combination Treatment., PLoS ONE

TIVOZANIB FLT1

Interaction Score: 0.77

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Notes

Novel drug target Established target

Trial Name AV-951

PMIDs:
None found

Sources:
TALC MyCancerGenome TdgClinicalTrial ClearityFoundationClinicalTrial ChemblInteractions TTD
TIVOZANIB FLT4

Interaction Score: 0.74

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Notes

Trial Name AV-951

Novel drug target Established target

PMIDs:
None found

Sources:
TALC MyCancerGenome TdgClinicalTrial ClearityFoundationClinicalTrial ChemblInteractions TTD
TIVOZANIB KDR

Interaction Score: 0.49

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name AV-951

Novel drug target Established target

Mechanism of Interaction Vascular endothelial growth factor receptor inhibitor

PMIDs:
None found

Sources:
TALC MyCancerGenome TdgClinicalTrial ClearityFoundationClinicalTrial ChemblInteractions TTD
TIVOZANIB BRAF

Interaction Score: 0.21

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy PLX4720 + Tivozanib

Indication/Tumor Type melanoma

Response Type sensitive

PMIDs:
26461489

Sources:
JAX-CKB
TIVOZANIB ERBB2

Interaction Score: 0.14

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy 23814 + Tivozanib

Indication/Tumor Type breast cancer

Response Type sensitive

PMIDs:
25995436

Sources:
JAX-CKB
TIVOZANIB YES1

Interaction Score: 0.05

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC

MyCancerGenome: TIVOZANIB
- Version: 20-Jun-2017
Alternate Names:

KRN951 Development Name

AV-951 Development Name

TIVOZANIB Generic Name

Drug Info:

Drug Class Kinase Inhibitors

Publications:
TdgClinicalTrial: TIVOZANIB
- Version: January-2014
Alternate Names:

Drug Info:

Drug Indications antineoplastic agent

Drug Class Small molecule

FDA Approval not approved

Publications:

JAX-CKB: Tivozanib

Version: 27-September-2017

Alternate Names:

Drug Info:

Publications:

Friedman et al., 2015, Landscape of Targeted Anti-Cancer Drug Synergies in Melanoma Identifies a Novel BRAF-VEGFR/PDGFR Combination Treatment., PLoS ONE

Proia et al., 2015, 23814, an Inhibitory Antibody of Ligand-Mediated Notch1 Activation, Modulates Angiogenesis and Inhibits Tumor Growth without Gastrointestinal Toxicity., Mol. Cancer Ther.

TALC: TIVOZANIB
- Version: 12-May-2016
Alternate Names:

TIVOZANIB Primary Drug Name

TIVOZANIB Drug Generic Name

TIVOPATH Drug Trade Name

Drug Info:

Publications:
DTC: TIVOZANIB
- Version: 02-September-2020
Alternate Names:

CHEMBL1289494 ChEMBL Drug ID

Drug Info:

Publications:
TTD: Tivozanib
- Version: 2020.06.01
Alternate Names:

D0W7JZ TTD Drug ID

Drug Info:

Publications:
ChemblDrugs: chembl:CHEMBL1289494
- Version: ChEMBL_27
Alternate Names:

Drug Info:

Publications:
ChemblInteractions: CHEMBL1289494
- Version: chembl_23
Alternate Names:

Drug Info:

Publications:
ClearityFoundationClinicalTrial: TIVOZANIB
- Version: 15-June-2013
Alternate Names:

Drug Info:

Publications:

Trial Name	AV-951
Novel drug target	Established target
Mechanism of Interaction	Vascular endothelial growth factor receptor inhibitor

combination therapy	PLX4720 + Tivozanib
Indication/Tumor Type	melanoma
Response Type	sensitive

combination therapy	23814 + Tivozanib
Indication/Tumor Type	breast cancer
Response Type	sensitive

KRN951	Development Name
AV-951	Development Name
TIVOZANIB	Generic Name

TIVOZANIB	Primary Drug Name
TIVOZANIB	Drug Generic Name
TIVOPATH	Drug Trade Name

TIVOZANIB Drug Record

TIVOZANIB chembl:CHEMBL1289494 ApprovedAntineoplastic

Alternate Names:

Drug Info:

Publications:

TIVOZANIB FLT1

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Notes Novel drug target Established target Trial Name AV-951

PMIDs: None found

Sources: TALC MyCancerGenome TdgClinicalTrial ClearityFoundationClinicalTrial ChemblInteractions TTD

TIVOZANIB FLT4

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Notes Trial Name AV-951 Novel drug target Established target

PMIDs: None found

Sources: TALC MyCancerGenome TdgClinicalTrial ClearityFoundationClinicalTrial ChemblInteractions TTD

TIVOZANIB KDR

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Trial Name AV-951 Novel drug target Established target Mechanism of Interaction Vascular endothelial growth factor receptor inhibitor

PMIDs: None found

Sources: TALC MyCancerGenome TdgClinicalTrial ClearityFoundationClinicalTrial ChemblInteractions TTD

TIVOZANIB BRAF

Interaction Types & Directionality: n/a

Interaction Info: combination therapy PLX4720 + Tivozanib Indication/Tumor Type melanoma Response Type sensitive

PMIDs: 26461489

Sources: JAX-CKB

TIVOZANIB ERBB2

Interaction Types & Directionality: n/a

Interaction Info: combination therapy 23814 + Tivozanib Indication/Tumor Type breast cancer Response Type sensitive

PMIDs: 25995436

Sources: JAX-CKB

TIVOZANIB YES1

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: DTC

MyCancerGenome: TIVOZANIB

Alternate Names: KRN951 Development Name AV-951 Development Name TIVOZANIB Generic Name

Drug Info: Drug Class Kinase Inhibitors

Publications:

TdgClinicalTrial: TIVOZANIB

Alternate Names:

Drug Info: Drug Indications antineoplastic agent Drug Class Small molecule FDA Approval not approved

Publications:

JAX-CKB: Tivozanib

Alternate Names:

Drug Info:

TALC: TIVOZANIB

Alternate Names: TIVOZANIB Primary Drug Name TIVOZANIB Drug Generic Name TIVOPATH Drug Trade Name

Drug Info:

Publications:

DTC: TIVOZANIB

Alternate Names: CHEMBL1289494 ChEMBL Drug ID

Drug Info:

Publications:

TTD: Tivozanib

Alternate Names: D0W7JZ TTD Drug ID

Drug Info:

Publications:

ChemblDrugs: chembl:CHEMBL1289494

Alternate Names:

Drug Info:

Publications:

ChemblInteractions: CHEMBL1289494

Alternate Names:

Drug Info:

Publications:

ClearityFoundationClinicalTrial: TIVOZANIB

Alternate Names:

Drug Info:

Publications:

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Notes

Novel drug target Established target

Trial Name AV-951

PMIDs:
None found

Sources:
TALC MyCancerGenome TdgClinicalTrial ClearityFoundationClinicalTrial ChemblInteractions TTD

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Notes

Trial Name AV-951

Novel drug target Established target

PMIDs:
None found

Sources:
TALC MyCancerGenome TdgClinicalTrial ClearityFoundationClinicalTrial ChemblInteractions TTD

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name AV-951

Novel drug target Established target

Mechanism of Interaction Vascular endothelial growth factor receptor inhibitor

PMIDs:
None found

Sources:
TALC MyCancerGenome TdgClinicalTrial ClearityFoundationClinicalTrial ChemblInteractions TTD

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy PLX4720 + Tivozanib

Indication/Tumor Type melanoma

Response Type sensitive

PMIDs:
26461489

Sources:
JAX-CKB

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy 23814 + Tivozanib

Indication/Tumor Type breast cancer

Response Type sensitive

PMIDs:
25995436

Sources:
JAX-CKB

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
DTC

Alternate Names:

KRN951 Development Name

AV-951 Development Name

TIVOZANIB Generic Name

Drug Info:

Drug Class Kinase Inhibitors

Drug Info:

Drug Indications antineoplastic agent

Drug Class Small molecule

FDA Approval not approved

Alternate Names:

TIVOZANIB Primary Drug Name

TIVOZANIB Drug Generic Name

TIVOPATH Drug Trade Name

Alternate Names:

CHEMBL1289494 ChEMBL Drug ID

Alternate Names:

D0W7JZ TTD Drug ID